KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other financing activities (2018 - 2024)

Historic Other financing activities for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q3 2024 value amounting to -$1.8 million.

  • Alnylam Pharmaceuticals' Other financing activities fell 12124.08% to -$1.8 million in Q3 2024 from the same period last year, while for Dec 2025 it was -$3.1 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2025, which is N/A changed from last year.
  • As of Q3 2024, Alnylam Pharmaceuticals' Other financing activities stood at -$1.8 million, which was down 12124.08% from -$1.3 million recorded in Q2 2024.
  • In the past 5 years, Alnylam Pharmaceuticals' Other financing activities registered a high of $8.3 million during Q3 2023, and its lowest value of -$16.3 million during Q4 2023.
  • For the 5-year period, Alnylam Pharmaceuticals' Other financing activities averaged around $3.5 million, with its median value being $4.2 million (2020).
  • Its Other financing activities has fluctuated over the past 5 years, first soared by 11428.57% in 2022, then tumbled by 31777.33% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Other financing activities (Quarter) stood at $4.2 million in 2020, then fell by 16.67% to $3.5 million in 2021, then soared by 114.29% to $7.5 million in 2022, then crashed by 317.77% to -$16.3 million in 2023, then surged by 89.16% to -$1.8 million in 2024.
  • Its Other financing activities stands at -$1.8 million for Q3 2024, versus -$1.3 million for Q2 2024 and $3.1 million for Q1 2024.